文献速递遗传性与小管间质肾病

Nedosiran在原发性高草酸尿症中的首次人体药效与暴露-反应研究

Safety, pharmacodynamics, and exposure-response modeling results from a first-in-human phase 1 study of nedosiran (PHYOX1) in primary hyperoxaluria.
PubMed 文献 · Kidney Int · 2021-09-02

PHYOX1是一项两部分随机单次递增剂量1期研究,纳入25名健康受试者和18例PH1或PH2患者,评估皮下注射nedosiran的安全性、药代动力学、药效学及暴露-反应。未发现显著安全性问题,单次给药后患者24小时尿草酸平均最大降幅55%,33%患者达到正常水平。基于模型模拟,成人每月固定剂量160 mg(游离酸)与最多模拟个体达到正常或接近正常尿草酸排泄相关。

要点

  • 单次nedosiran安全性可接受,注射部位反应常见但无显著安全性担忧。
  • PH1/PH2患者单次给药后24小时尿草酸平均最大降幅55%,33%恢复正常。
  • 模型提示成人每月160 mg固定剂量可能优化尿草酸应答。

核心结论

  • 单次皮下注射nedosiran在PH1和PH2患者中显示可接受的安全性及与作用机制一致药效学效应。

研究设计与样本

  • 两部分、随机、单次递增剂量1期研究(PHYOX1),纳入25名健康受试者(A组)和18例PH1或PH2患者(B组)。
  • A组接受nedosiran 0.3、1.5、3.0、6.0、12.0 mg/kg或安慰剂,B组接受开放标签nedosiran 1.5、3.0或6.0 mg/kg。

主要发现

  • 未发现显著安全性问题;注射部位反应(给药后4小时或更晚)在A组发生率13.3%,B组27.8%。
  • B组各剂量队列从基线至第57天(研究结束)24小时尿草酸排泄平均最大降幅为55%(范围22%-100%)。
  • 33%的B组患者达到正常24小时尿草酸排泄。

关键数值与推荐

  • 基于可用建模与模拟数据,成人每月固定剂量nedosiran 160 mg(游离酸;相当于170 mg钠盐)与最高比例的模拟个体达到正常或接近正常24小时尿草酸排泄及最少尿草酸应答波动相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Primary hyperoxaluria (PH) is a family of ultra-rare autosomal recessive inherited disorders of hepatic glyoxylate metabolism characterized by oxalate overproduction. Nedosiran is an RNA interference agent that inhibits hepatic lactate dehydrogenase, the enzyme responsible for the common, final step of oxalate production in all three genetic subtypes of PH. Here, we assessed in a two-part, randomized, single-ascending-dose, phase 1 study (PHYOX1) the safety, pharmacokinetics, pharmacodynamics, and exposure-response of subcutaneous nedosiran in 25 healthy participants (Group A) and 18 patients with PH1 or PH2 (Group B). Group A received nedosiran (0.3, 1.5, 3.0, 6.0, then 12.0 mg/kg) or placebo, and Group B received open-label nedosiran (1.5, 3.0, or 6.0 mg/kg). No significant safety concerns were identified. Injection site reactions (four or more hours post dose) occurred in 13.3% of participants in Group A and 27.8% of participants in Group B. Mean maximum reduction in 24-hour urinary oxalate excretion from baseline to day 57 (end of study) across Group B dose cohorts was 55% (range: 22%-100%) after single-dose nedosiran, with 33% participants reaching normal 24-hour urinary oxalate excretion. Based on the available modeling and simulation data, a fixed monthly dose of nedosiran 160 mg (free acid; equivalent to 170 mg sodium salt) in adults was associated with the highest proportion of simulated individuals achieving normal or near-normal 24-hour urinary oxalate excretion and fewest fluctuations in urinary oxalate response. Thus, single-dose nedosiran demonstrated acceptable safety and evidence of a pharmacodynamic effect in both PH1 and PH2 subpopulations consistent with its mechanism of action.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Hoppe B, Koch A, Cochat P, et al. Safety, pharmacodynamics, and exposure-response modeling results from a first-in-human phase 1 study of nedosiran (PHYOX1) in primary hyperoxaluria. Kidney Int. 2021. PMID: 34481803. doi:10.1016/j.kint.2021.08.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。